» Articles » PMID: 27196002

Exosome-mediated Small RNA Delivery for Gene Therapy

Overview
Publisher Wiley
Date 2016 May 20
PMID 27196002
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Small RNAs, including small interfering RNAs (siRNA) and microRNAs (miRNA), are emerging as promising therapeutic drugs against a wide array of diseases. The key obstacle for the successful clinical application of small RNAs is to develop a safe delivery system directed at the target tissues only. Current small RNA transfer techniques use viruses or synthetic agents as delivery vehicles. The replacement of these delivery vehicles with a low toxicity and high target-specific approach is essential for making small RNA therapy feasible. Because exosomes have the intrinsic ability to traverse biological barriers and to naturally transport functional small RNAs between cells, they represent a novel and exciting delivery vehicle for the field of small RNA therapy. As therapeutic delivery agents, exosomes will potentially be better tolerated by the immune system because they are natural nanocarriers derived from endogenous cells. Furthermore, exosomes derived from genetically engineered cells can deliver small RNAs to target tissues and cells. Thus, exosome-based delivery of small RNAs may provide an untapped, effective delivery strategy to overcome impediments such as inefficiency, nonspecificity, and immunogenic reactions. In this review, we briefly describe how exosomal small RNAs function in recipient cells. Furthermore, we provide an update and overview of new findings that reveal the potential applications of exosome-based small RNA delivery as therapeutics in clinical settings. WIREs RNA 2016, 7:758-771. doi: 10.1002/wrna.1363 For further resources related to this article, please visit the WIREs website.

Citing Articles

Treatment of neurological pathology and inflammation in Machado-Joseph disease through in vivo self-assembled siRNA.

Li Z, Du X, Yang Y, Zhang L, Chen P, Kan Y Brain. 2024; 148(3):817-832.

PMID: 39315766 PMC: 11884698. DOI: 10.1093/brain/awae304.


Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm.

Beigi A, Naghib S, Matini A, Tajabadi M, Mozafari M Curr Gene Ther. 2024; 25(2):92-112.

PMID: 38778601 DOI: 10.2174/0115665232292768240503050508.


Harnessing exosomes in theranostic applications: advancements and insights in gastrointestinal cancer research.

Shojaeian A, Naeimi Torshizi S, Parsapasand M, Amjad Z, Khezrian A, Alibakhshi A Discov Oncol. 2024; 15(1):162.

PMID: 38743146 PMC: 11093943. DOI: 10.1007/s12672-024-01024-x.


Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS.

Vaswani C, Simone J, Pavelick J, Wu X, Tan G, Ektesabi A Int J Mol Sci. 2024; 25(5).

PMID: 38474059 PMC: 10931977. DOI: 10.3390/ijms25052812.


Long non-coding RNAs with essential roles in neurodegenerative disorders.

Xiong W, Lu L, Li J Neural Regen Res. 2023; 19(6):1212-1220.

PMID: 37905867 PMC: 11467921. DOI: 10.4103/1673-5374.385850.